Patents by Inventor David C. Myles

David C. Myles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220370421
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: December 6, 2021
    Publication date: November 24, 2022
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20220265616
    Abstract: Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.
    Type: Application
    Filed: July 6, 2020
    Publication date: August 25, 2022
    Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
  • Patent number: 11229630
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: January 25, 2022
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20210059991
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: April 17, 2020
    Publication date: March 4, 2021
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Patent number: 10624878
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: April 21, 2020
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20190247372
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 15, 2019
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Patent number: 10292971
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 21, 2019
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20180289679
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 11, 2018
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20170362210
    Abstract: The present disclosure provides a compound of Formula I: or a pharmaceutically acceptable salt wherein X, R1-R8, Y1-Y5, m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders mediated by estrogen, and other disorders, as described herein. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 21, 2017
    Applicant: PFIZER INC.
    Inventors: Peter J. KUSHNER, David C. MYLES, Cyrus L. HARMON, Leslie Carol HODGES GALLAGHER
  • Publication number: 20160311805
    Abstract: The present disclosure provides a compound of Formula I: or a pharmaceutically acceptable salt wherein X, R1-R8, Y1-Y5, m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders mediated by estrogen, and other disorders, as described herein. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Applicant: PFIZER INC.
    Inventors: Peter J. KUSHNER, David C. MYLES, Cyrus L. HARMON, Leslie Carol HODGES GALLAGHER
  • Publication number: 20150197506
    Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
    Type: Application
    Filed: March 17, 2015
    Publication date: July 16, 2015
    Applicant: OLEMA PHARMACEUTICALS, INC.
    Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
  • Patent number: 9018244
    Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: April 28, 2015
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
  • Patent number: 8193241
    Abstract: 6- and 7-substituted coumarin and related 6- and 7-substituted 1H-quinolin-2-one compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the 7-substituted coumarin and related 7-substituted 1H-quinolin-2-one compounds mimic or exceed the high level of pharmacological activity of discodermolide. In other embodiments, their preparation involves more readily available materials, higher yield processes and/or simpler synthetic sequences. In yet other embodiments, the compounds of the invention represent structurally simpler, therapeutically active analogues of discodermolide than heretofore known and may be useful as microtubule stabilizers and, inter alia, for treating and/or preventing cancer and other diseases, disorders, and/or conditions mediated by the stabilization of microtubules.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: June 5, 2012
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Amos B. Smith, III, Simon J. Shaw, David C. Myles
  • Patent number: 8063021
    Abstract: Compounds according to formula I wherein m is 0 or 1; X is and R1, R2, R3 R4, and R5 are as defined herein, are useful as anti-infective agents.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: November 22, 2011
    Assignee: Kosan Biosciences Incorporated
    Inventors: Yong Li, Yandong Li, Yan Zhu, Chaitan Khosla, David C. Myles
  • Publication number: 20110172220
    Abstract: 6- and 7-substituted coumarin and related 6- and 7-substituted 1H-quinolin-2-one compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the 7-substituted coumarin and related 7-substituted 1H-quinolin-2-one compounds mimic or exceed the high level of pharmacological activity of discodermolide. In other embodiments, their preparation involves more readily available materials, higher yield processes and/or simpler synthetic sequences. In yet other embodiments, the compounds of the invention represent structurally simpler, therapeutically active analogues of discodermolide than heretofore known and may be useful as microtubule stabilizers and, inter alia, for treating and/or preventing cancer and other diseases, disorders, and/or conditions mediated by the stabilization of microtubules.
    Type: Application
    Filed: November 15, 2010
    Publication date: July 14, 2011
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Amos B. Smith, III, Simon J. Shaw, David C. Myles
  • Patent number: 7655808
    Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: February 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven D. Dong, Daniel V. Santi, David C. Myles, Brian Hearn
  • Patent number: 7582611
    Abstract: Compounds having a structure according to formula (I) where RA, RB, RC, RD, RE, and RF are as defined herein, are useful as prokinetic agents.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: September 1, 2009
    Assignee: Pfizer Inc.
    Inventors: Yaoquan Liu, Christopher Carreras, David C. Myles, Yong Li, Simon James Shaw, Hong Fu, Yue Chen, Hao Zheng, Yandong Li, Mark A. Burlingame
  • Publication number: 20090111869
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Application
    Filed: June 18, 2008
    Publication date: April 30, 2009
    Applicant: Kosan Biosciences, Inc.
    Inventors: Daniel SANTI, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Publication number: 20090042837
    Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.
    Type: Application
    Filed: September 30, 2008
    Publication date: February 12, 2009
    Inventors: Steven Dong, Daniel V. Santi, David C. Myles, Brian Hearn
  • Patent number: 7446196
    Abstract: Leptomycin-type compounds according to Formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: November 4, 2008
    Assignee: Kosan Biosciences, Incorporated
    Inventors: Steven Dong, Daniel V. Santi, David C. Myles, Brian Hearn